Evidence & regulatory context
- Mechanism
- INHIBITOR of cyclooxygenase-1 (CHEMBL4133) and cyclooxygenase-2 (CHEMBL4033); higher activity towards COX-2 vs COX-1. Approved veterinary (EMA, Trocoxil).
- Target
- Cyclooxygenase-1 (CHEMBL4133); Cyclooxygenase-2 (CHEMBL4033)
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL record
- CHEMBL28527 ↗
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Mavacoxib; Trocoxil; PHA-739521
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatOtherSprague-DawleyMaleAcute administration at the time of injury and scaffold implantation
Model: Surgically created volumetric muscle loss defect treated with an implanted biologic scaffold
Adjunct COX-2 inhibition with mavacoxib did not alter the baseline functional or histomorphological repair outcomes achieved by the biologic scaffold in volumetric muscle loss.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
